Illumina Inc (ILMN)
Illumina Inc (ILMN) carries a ŷRobot AI score of 80 out of 100. The model's fair value estimate is $346.90, 27.7% above the last close of $271.76. The chart signal reads Bearish.
| Metric | ILMN |
|---|---|
| AI score | 80 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $346.90 |
| Upside to fair value | 27.7% |
| Previous close | $271.76 |
| P/E | 50.96 |
| Price / sales | 8.93 |
| Market cap | $41.78B |
| EPS | 5.37 |
| Revenue growth | -2.0% |
| 1-year price change | 4.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about ILMN
Is ILMN overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates Illumina Inc (ILMN) at $346.90 against a last close of $271.76, implying 27.7% upside to the model's estimate.
Is ILMN's chart signal bullish or bearish?
The chart-signal model classifies ILMN as Neutral as of Oct 14, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is ILMN's ŷRobot AI score?
ILMN scores 80 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is ILMN stock expensive on P/E and P/S?
ILMN trades at 51.0 times earnings and 8.9 times sales as of Oct 14, 2026.
What does ILMN's seasonal forecast show?
ŷRobot's seasonal forecast curve for ILMN reads +0.7% at 30 days, +7.2% at 90 days, and +4.4% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ILMN growing?
Illumina Inc's revenue growth is -2.0% and free-cash-flow growth is -2.3% on the latest reported figures.
ILMN chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.